DOCSLIB.ORG

Antiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel As Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel As Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer Cells Published OnlineFirst June 30, 2014; DOI: 10.1158/1535-7163.MCT-14-0265 Molecular Cancer Cancer Biology and Signal Transduction Therapeutics Antiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel as Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer Cells Olga Azarenko, Gregoriy Smiyun, Jeffrey Mah, Leslie Wilson, and Mary Ann Jordan Abstract Cabazitaxel, a novel chemotherapeutic taxane, is effective against docetaxel-resistant cells and tumors. It is approved for treatment of metastatic hormone-refractory prostate cancer in patients pretreated with docetaxel. Objective responses have been observed in many other cancers, including pretreated metastatic breast cancer. Cabazitaxel and docetaxel share a high degree of structural similarity. The basis for cabazitaxel’s efficacy is unclear, and its mechanism has not been described. We compared the effects of cabazitaxel and docetaxel on MCF7 human breast cancer cells expressing fluorescent tubulin. Both drugs Æ Æ inhibited cell proliferation (IC50s, cabazitaxel, 0.4 0.1 nmol/L, docetaxel, 2.5 0.5 nmol/L) and arrested cells in metaphase by inducing mitotic spindle abnormalities. Drug concentrations required for half- maximal mitotic arrest at 24 hours were similar (1.9 nmol/L cabazitaxel and 2.2 nmol/L docetaxel). Cabazitaxel suppressed microtubule dynamic instability significantly more potently than docetaxel. In particular, cabazitaxel (2 nmol/L) suppressed the microtubule shortening rate by 59% (compared with 49% for 2 nmol/L docetaxel), the growing rate by 33% (vs. 19%), and overall dynamicity by 83% (vs. 64%). Cabazitaxel was taken up into cells significantly faster than docetaxel, attaining an intracellular concen- tration of 25 mmol/L within 1 hour, compared with 10 hours for docetaxel. Importantly, after washing, the intracellular cabazitaxel concentration remained high, whereas the docetaxel concentration was signifi- cantly reduced. The data indicate that the potency of cabazitaxel in docetaxel-resistant tumors is due to stronger suppression of microtubule dynamics, faster drug uptake, and better intracellular retention than occurs with docetaxel. Mol Cancer Ther; 13(8); 2092–103. Ó2014 AACR. Introduction acquired resistance to these drugs (5–7). Paclitaxel and The chemotherapeutic taxanes paclitaxel (Taxol) and docetaxel both have a high affinity for multidrug resistance docetaxel (Taxotere) play important, well-established roles proteins (7–9). in the treatment of a variety of malignancies, including a Cabazitaxel (Jevtana) is a novel third-generation semi- broad spectrum of solid tumors (1, 2). Paclitaxel is widely synthetic analog of docetaxel (8, 10–12). Structurally, used for the treatment of breast, ovarian, and non–small cell cabazitaxel and docetaxel are very similar with the excep- lung cancer, whereas docetaxel-containing regimens are tion of 2 methoxy side chains in cabazitaxel that substitute indicated for metastatic prostate, breast, and other cancers for hydroxyl groups in docetaxel (Fig. 1A). In preclinical (3, 4). Despite the clinical success of microtubule-targeting testing, cabazitaxel demonstrated activity in both doce- agents, toxicity (mostly neutropenia and neurotoxicity), taxel-sensitive and docetaxel-resistant cancers (13, 14). In complex formulations (use of CremophorEL), and limited addition, the terminal half-life for cabazitaxel in humans oral bioavailability restrict their clinical use in cancer ther- is 95 hours (15) as compared with 12 hours for docetaxel apy (1). Many tumor types are refractory and/or develop (16). Cabazitaxel was approved in 2010 as a second-line treatment in men with metastatic castration-resistant prostate cancer that failed docetaxel-containing regimens Authors' Affiliation: Department of Molecular, Cellular, and Developmen- (17, 18). Like paclitaxel and docetaxel, cabazitaxel stabi- tal Biology and the Neuroscience Research Institute, University of Cali- fornia Santa Barbara, Santa Barbara, California lizes microtubules against cold-induced depolymeriza- tion and promotes assembly of tubulin into microtubules Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/). (12, 14). Microtubules are major components of the eukaryotic Corresponding Author: Mary Ann Jordan, Neuroscience Research Insti- tute, Life Sciences Building, Room 1117, University of California, Santa cytoskeleton. They are involved in cell division, migra- Barbara, Santa Barbara, CA 93106. Phone: 805-893-5317; Fax: 805-893- tion, signaling, and intracellular trafficking and are 8094; E-mail: [email protected] important in cancer cell proliferation and metastasis (2). doi: 10.1158/1535-7163.MCT-14-0265 Microtubules are composed of ab-tubulin heterodimers Ó2014 American Association for Cancer Research. that link together noncovalently during polymerization to 2092 Mol Cancer Ther; 13(8) August 2014 Downloaded from mct.aacrjournals.org on October 1, 2021. © 2014 American Association for Cancer Research. Published OnlineFirst June 30, 2014; DOI: 10.1158/1535-7163.MCT-14-0265 Mechanism of Action of the Novel Taxane Cabazitaxel AB CD EF Figure 1. Concentration-dependent effects of cabazitaxel and docetaxel (A) on inhibition of proliferation (B), induction of cell death (C), mitotic arrest (D), and G2–M arrest (E and F) in MCF7 cells. A, the chemical structures of docetaxel (Taxotere) and cabazitaxel (Jevtana). In cabazitaxel methoxy side chains substitute for hydroxyl groups in docetaxel (highlighted in red). B, cells were incubated with cabazitaxel (-&-) or docetaxel (-^-) for 72 hours, and inhibition of proliferation was measured using a sulforhodamine B assay. Cabazitaxel and docetaxel inhibited cell proliferation with IC50 values of 0.4 Æ 0.1 (SEM) nmol/L and 2.5 Æ 0.5 (SEM) nmol/L, respectively. C, cells were incubated with vehicle control (x), cabazitaxel for 24 (-&-), 48 (-*-), and 72 (-~-) hours, and docetaxel for 24 (-&-), 48 (-*-), and 72 (-~-) hours and the population of combined apoptotic/dead cells was determined by flow cytometry. Controls at 24, 48, and 72 hours displayed similar levels of apoptosis (1.5%, -x-). D, cells were incubated with cabazitaxel (-&-) and docetaxel (-^-) for 24 hours, and the percentage of mitotic cells was determined using immunofluorescence microscopy. Cabazitaxel and docetaxel induced mitotic arrest with IC50's of 1.9 and 2.2 nmol/L, respectively. Cells were incubated with cabazitaxel (CBZ) for 24 (-&-), 48 (-*-), and 72 (-~-) hours (E), and with docetaxel (DOC) for 24 (-&-), 48 (-*-), and 72 (-~-) hours (F), and the population of G2–M cells was determined by flow cytometry. Control (CTR) cells in ÃÃ ÃÃÃ G2–Mat24(^), 48 (^), and 72 hours gray diamond. Results are means and SEM of at least 3 independent experiments. , P < 0.01; , P < 0.001 by the Student t test. www.aacrjournals.org Mol Cancer Ther; 13(8) August 2014 2093 Downloaded from mct.aacrjournals.org on October 1, 2021. © 2014 American Association for Cancer Research. Published OnlineFirst June 30, 2014; DOI: 10.1158/1535-7163.MCT-14-0265 Azarenko et al. form 25-nm-diameter hollow cylindrical filaments (19). nificantly more effective suppression of microtubule Microtubules are highly dynamic structures that alternate dynamics, rapid intracellular uptake, and prolonged between periods of growth and shortening through the drug retention play significant roles in its efficacy in addition or loss of tubulin subunits at microtubule ends docetaxel-resistant tumors. (20). This nonequilibrium behavior is termed "dynamic instability" and occurs both in vitro with microtubules reassembled from purified tubulin and in cells. Dynamic Materials and Methods microtubules are especially important during mitosis Materials when they are required for the capture and complex Chemicals and materials were from Sigma-Aldrich movements of chromosomes, including chromosome unless otherwise noted. Cabazitaxel and docetaxel were alignment during metaphase and separation during ana- provided by Sanofi-Aventis (France) and stored as ali- phase (21, 22). Dynamic spindle microtubules are crucial quots of 10 mmol/L stock solutions in DMSO at À20C. to successful cell division, making cells highly susceptible Stock solutions were diluted in DMSO to 1 mmol/L and to drugs that suppress microtubule dynamic instability at further diluted in cell culture medium. low concentrations (23, 24). The taxanes, including paclitaxel and docetaxel, are Cell culture microtubule-stabilizing antitumor drugs that enhance MCF7 human breast adenocarcinoma cells were cul- microtubule polymerization at high concentrations (25, tured in DMEM with 10% fetal bovine serum (Atlanta 26). All taxanes bind to the same or to an overlapping Biologicals, Inc.), 1% final concentration of nonessential taxoid-binding site on b-tubulin, located on the inner amino acids, 100 units/mL penicillin, and 100 mg/mL surface of the microtubule (27, 28). Taxanes and other streptomycin at 37 C, 5.5% CO2. Shortly after purchase microtubule-targeting drugs inhibit cancer cell prolif- (ATCC, 2007), the cells were transfected with an enhanced eration by binding to microtubules and suppressing green fluorescent protein EGFP-a-tubulin vector (Clon- microtubule dynamics during the particularly vulner- tech Laboratories; ref. 34). The EGFP-a-tubulin-expres- able mitotic stage of the cell cycle without significantly sing MCF7 cells were indistinguishable from unmodified altering the mass or organization of microtubules (26). MCF7 cells except for their fluorescent
Load more

Recommended publications
  • Re-Visiting Hypersensitivity Reactions to Taxanes: a Comprehensive Review
    Clinic Rev Allerg Immunol DOI 10.1007/s12016-014-8416-0 Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review Matthieu Picard & Mariana C. Castells # Springer Science+Business Media New York 2014 Abstract Taxanes (a class of chemotherapeutic agents) Keywords Taxane . Paclitaxel . Taxol . Docetaxel . are an important cause of hypersensitivity reactions Taxotere . Nab-paclitaxel . Abraxane . Cabazitaxel . (HSRs) in cancer patients. During the last decade, the Chemotherapy . Hypersensitivity . Allergy . Skin test . development of rapid drug desensitization has been key Desensitization . Challenge . Diagnosis . Review . IgE . to allow patients with HSRs to taxanes to be safely re- Complement . Mechanism treated although the mechanisms of these HSRs are not fully understood. Earlier studies suggested that solvents, such as Cremophor EL used to solubilize paclitaxel, Introduction were responsible for HSRs through complement activa- tion, but recent findings have raised the possibility that Hypersensitivity reactions (HSRs) to chemotherapy are in- some of these HSRs are IgE-mediated. Taxane skin creasingly common and represent an important impediment testing, which identifies patients with an IgE-mediated to the care of cancer patients as they may entail serious sensitivity, appears as a promising diagnostic and risk consequences and prevent patients from being treated with stratification tool in the management of patients with the most efficacious agent against their cancer [1]. During the HSRs to taxanes. The management of patients following last decade, different groups have developed rapid drug de- a HSR involves risk stratification and re-exposure could sensitization (RDD) protocols that allow the safe re- be performed either through rapid drug desensitization introduction of a chemotherapeutic agent to which a patient or graded challenge based on the severity of the initial is allergic, and their use have recently been endorsed by the HSR and the skin test result.
    [Show full text]
  • Jevtana® (Cabazitaxel)
    AUSTRALIAN PRODUCT INFORMATION – JEVTANA® (CABAZITAXEL) 1 NAME OF THE MEDICINE Cabazitaxel 2 QUALITATIVE AND QUANTITATIVE COMPOSITION The concentrated solution for injection contains 60 mg cabazitaxel in 1.5 mL polysorbate 80. Diluent contains 13% w/w ethanol in 4.5 mL water for injections. Excipients of known effect: Diluent contains 13% w/w ethanol. For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM The concentrated solution for injection is a clear oily yellow to brownish yellow solution. The diluent is a clear, colourless solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen. 4.2 DOSE AND METHOD OF ADMINISTRATION The use of Jevtana should be confined to units specialised in the administration of cytotoxics and it should only be administered under the supervision of a physician experienced in the use of anticancer chemotherapy. Premedication Premedicate at least 30 minutes prior to each administration of Jevtana with the following intravenous medications to reduce the risk and severity of a hypersensitivity reaction: jevtana-ccdsv10-piv11-10nov20 Page 1 of 26 antihistamine (equivalent to dexchlorpheniramine 5 mg or diphenhydramine 25 mg or equivalent), corticosteroid (dexamethasone 8 mg or equivalent) and with H2 antagonist (ranitidine or equivalent). Antiemetic prophylaxis is recommended and can be given orally or intravenously as needed (see Section 4.4 Special warnings and precautions for use). Recommended Dosage The recommended dose of Jevtana is 20 mg/m2 administered as a 1-hour intravenous infusion every 3 weeks in combination with oral prednisone (or prednisolone) 10 mg administered daily throughout Jevtana treatment.
    [Show full text]
  • BC Cancer Benefit Drug List September 2021
    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
    [Show full text]
  • Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics
    Review Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics Joel Mintz 1,†, Anastasia Vedenko 2,†, Omar Rosete 3 , Khushi Shah 4, Gabriella Goldstein 5 , Joshua M. Hare 2,6,7 , Ranjith Ramasamy 3,6,* and Himanshu Arora 2,3,6,* 1 Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Davie, FL 33328, USA; [email protected] 2 John P Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] (A.V.); [email protected] (J.M.H.) 3 Department of Urology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] 4 College of Arts and Sciences, University of Miami, Miami, FL 33146, USA; [email protected] 5 College of Health Professions and Sciences, University of Central Florida, Orlando, FL 32816, USA; [email protected] 6 The Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA 7 Department of Medicine, Cardiology Division, Miller School of Medicine, University of Miami, Miami, FL 33136, USA * Correspondence: [email protected] (R.R.); [email protected] (H.A.) † These authors contributed equally to this work. Abstract: Nitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical functions in the body. There are markedly conflicting findings in the literature regarding the bimodal effects of NO in carcinogenesis and tumor progression, which has important consequences for treatment. Several preclinical and clinical studies have suggested that both pro- and antitumori- Citation: Mintz, J.; Vedenko, A.; genic effects of NO depend on multiple aspects, including, but not limited to, tissue of generation, the Rosete, O.; Shah, K.; Goldstein, G.; level of production, the oxidative/reductive (redox) environment in which this radical is generated, Hare, J.M; Ramasamy, R.; Arora, H.
    [Show full text]
  • Filed by Cell Therapeutics, Inc. Pursuant to Rule 425 Under The
    Filed by Cell Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant Rule 14a-12 Of the Securities Exchange Act of 1934 Subject Company: Cell Therapeutics, Inc. Commission File No.: 001-12465 The following is a transcript of a presentation given by Cell Therapeutics, Inc. at its annual meeting of shareholders, held on June 20, 2003. Moderator: Jim Bianco Operator: Good day everyone and welcome to the Cell Therapeutics annual shareholder meeting. As a reminder, this call is being recorded. We’ll soon be going live to Seattle where the call will begin shortly. Please stand by. Jim Bianco: Welcome. My name is Jim Bianco. I’m the President and CEO of Cell Therapeutics. Welcome to our 2003 shareholders meeting. Our business meeting agenda today is to approve the minutes, elect the directors, and approve the equity incentive plan as well as the amendment to the employees stock purchase plan, and ratify the selection of E&Y as independent auditors. Mike Kennedy, the Secretary of the company, will act as secretary of this meeting, and George Pabst has been appointed inspector of elections to examine and count proxies and ballots. At the conclusion of the business portion of today’s meeting, members of management will present highlights from the past year and outline some of our future milestones and objectives for the next 12 to 18 months. At this time, I’d like to call the meeting to order. Let me begin by introducing our directors who are present today and let me start by saying that Dr.
    [Show full text]
  • Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: from Discovery to Implementation
    G C A T T A C G G C A T genes Review Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation Reka Varnai 1,2, Leena M. Koskinen 3, Laura E. Mäntylä 3, Istvan Szabo 4,5, Liesel M. FitzGerald 6 and Csilla Sipeky 3,* 1 Department of Primary Health Care, University of Pécs, Rákóczi u 2, H-7623 Pécs, Hungary 2 Faculty of Health Sciences, Doctoral School of Health Sciences, University of Pécs, Vörösmarty u 4, H-7621 Pécs, Hungary 3 Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, FI-20520 Turku, Finland 4 Institute of Sport Sciences and Physical Education, University of Pécs, Ifjúság útja 6, H-7624 Pécs, Hungary 5 Faculty of Sciences, Doctoral School of Biology and Sportbiology, University of Pécs, Ifjúság útja 6, H-7624 Pécs, Hungary 6 Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania 7000, Australia * Correspondence: csilla.sipeky@utu.fi Received: 17 June 2019; Accepted: 5 August 2019; Published: 8 August 2019 Abstract: Prostate cancer is the fifth leading cause of male cancer death worldwide. Although docetaxel chemotherapy has been used for more than fifteen years to treat metastatic castration resistant prostate cancer, the high inter-individual variability of treatment efficacy and toxicity is still not well understood. Since prostate cancer has a high heritability, inherited biomarkers of the genomic signature may be appropriate tools to guide treatment. In this review, we provide an extensive overview and discuss the current state of the art of pharmacogenomic biomarkers modulating docetaxel treatment of prostate cancer. This includes (1) research studies with a focus on germline genomic biomarkers, (2) clinical trials including a range of genetic signatures, and (3) their implementation in treatment guidelines.
    [Show full text]
  • Exosomes and Breast Cancer Drug Resistance Xingli Dong1,2, Xupeng Bai 2,3,Jieni2,3,Haozhang 4,Weiduan5, Peter Graham2,3 Andyongli 2,3,6
    Dong et al. Cell Death and Disease (2020) 11:987 https://doi.org/10.1038/s41419-020-03189-z Cell Death & Disease REVIEW ARTICLE Open Access Exosomes and breast cancer drug resistance Xingli Dong1,2, Xupeng Bai 2,3,JieNi2,3,HaoZhang 4,WeiDuan5, Peter Graham2,3 andYongLi 2,3,6 Abstract Drug resistance is a daunting challenge in the treatment of breast cancer (BC). Exosomes, as intercellular communicative vectors in the tumor microenvironment, play an important role in BC progression. With the in-depth understanding of tumor heterogeneity, an emerging role of exosomes in drug resistance has attracted extensive attention. The functional proteins or non-coding RNAs contained in exosomes secreted from tumor and stromal cells mediate drug resistance by regulating drug efflux and metabolism, pro-survival signaling, epithelial–mesenchymal transition, stem-like property, and tumor microenvironmental remodeling. In this review, we summarize the underlying associations between exosomes and drug resistance of BC and discuss the unique biogenesis of exosomes, the change of exosome cargo, and the pattern of release by BC cells in response to drug treatment. Moreover, we propose exosome as a candidate biomarker in predicting and monitoring the therapeutic drug response of BC and as a potential target or carrier to reverse the drug resistance of BC. ● Facts Tumor-derived exosomes mediate enhanced EMT and stem-like property of drug-resistant BC. ● ● Tumor-derived exosomes mediate the chemoresistance TME-derived exosomes mediate the tumor of BC by reducing the intracellular accumulation of microenvironmental remodeling that favors the drug resistance of BC. 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; chemotherapeutic drugs and delivering functional ● cargos that activate pro-survival signaling and The exosome is proposed as a candidate biomarker in unchecked cell cycle progression.
    [Show full text]
  • Psma-1-Doxorubicin Conjugates for Targeted Therapy of Prostate Cancer
    PSMA-1-DOXORUBICIN CONJUGATES FOR TARGETED THERAPY OF PROSTATE CANCER by NATALIE WALKER Submitted in partial fulfillment of the requirements for the degree of Master of Science Biomedical Engineering CASE WESTERN RESERVE UNIVERSITY May, 2019 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis of Natalie Walker candidate for the degree of Master of Science. Committee Chair Efstathios Karathanasis, PhD Committee Members James Basilion, PhD, Research Advisor Christopher Hoimes, DO Xinning Wang, PhD Date of Defense 14 January 2019 *We also certify that written approval has been obtained for any proprietary material contained therin. Contents List of Tables ..................................................................................................................... iv List of Figures ..................................................................................................................... v Abstract ............................................................................................................................... 1 Introduction ......................................................................................................................... 2 Table 1: Review of PSMA Expression in Nonprostate Malignancies. ................... 5 Figure 1: Outline of Structures of Three PSMA-1-Doxorubicin Prodrug Conjugates............................................................................................................... 8 Figure 2: Proposed Mechanism for Prodrug Release of
    [Show full text]
  • W O 2 11/ 28571Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date / 10 March 2011 (10.03.2011) W O 2 1 1/ 28 57 1 A l (51) International Patent Classification: (74) Agents: UDAL, Robert, P., Ph. D. et al; Morgan, Lewis A 43/02 (2006.01) & Bockius LLP, 1701 Market Street, Philadelphia, PA 19103 (US). (21) International Application Number: PCT/US20 10/046627 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, 25 August 2010 (25.08.2010) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (26) Publication Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (30) Priority Data: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 61/238,787 1 September 2009 (01 .09.2009) US NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicant (for all designated States except US): TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. TAPESTRY PHARMACEUTICALS, INC. [US/US]; 6304 Spine Road, Unit A, Boulder, CO 80301 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (72) Inventors; and GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (75) Inventors/ Applicants (for US only): MCCHESNEY, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, James, D.
    [Show full text]
  • Treatment of Taxane Acute Pain Syndrome (TAPS) in Cancer Patients Receiving Taxane-Based Chemotherapy—A Systematic Review
    Support Care Cancer (2016) 24:1583–1594 DOI 10.1007/s00520-015-2941-0 ORIGINAL ARTICLE Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy—a systematic review Ricardo Fernandes1 & Sasha Mazzarello2 & Habeeb Majeed3 & Stephanie Smith 2 & Risa Shorr4 & Brian Hutton5 & Mohammed FK Ibrahim1 & Carmel Jacobs1 & Michael Ong1 & Mark Clemons1,2,6 Received: 21 May 2015 /Accepted: 3 September 2015 /Published online: 19 September 2015 # Springer-Verlag Berlin Heidelberg 2015 Abstract randomized open-label trials 76 patients), and one was a ret- Background Taxane acute pain syndrome (TAPS) is charac- rospective study (10 patients). The agents investigated includ- terized by myalgias and arthralgias starting 1–3 days and last- ed gabapentin, amifostine, glutathione, and glutamine. Study ing 5–7 days after taxane-based chemotherapy. Despite nega- sizes ranged from 10 to 185 patients. Given the heterogeneity tively impacting patient’s quality of life, little is known about of study designs, a narrative synthesis of results was per- the optimal TAPS management. A systematic review of treat- formed. Neither glutathione (QoL, p = 0.30, no 95 % CI re- ment strategies for TAPS across all tumor sites was performed. ported) nor glutamine (mean improvement in average pain Methods Embase, Ovid MEDLINE(R), and the Cochrane was 0.8 in both treatment arms, p = 0.84, no 95 % CI reported) Central Register of Controlled Trials were searched from were superior to placebo. Response to amifostine (pain re- 1946 to October 2014 for trials reporting the effectiveness of sponse) and gabapentin (reduction in taxane-induced arthral- different treatments of TAPS in cancer patients receiving gias and myalgias) was 36 % (95 % CI, 16–61 %) and 90 % taxane-based chemotherapy.
    [Show full text]
  • CTI Corporate Presentation
    20062006 InvestInvest NorthwestNorthwest conferenceconference JamesJames A.A. Bianco,Bianco, M.D.M.D. PresidentPresident andand CEOCEO C E L L T H E R A P E U T I C S, I N C. (N A S D A Q : C T I C) ForwardForward LookingLooking StatementStatement This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The forward-looking statements contained in this presentation include statements about future financial and operating results, and risks and uncertainties that could affect CTI’s product and products under development. These statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. Therefore, actual outcomes and results may differ materially from what is expressed herein. In any forward-looking statement in which CTI expresses an expectation or belief as to future results, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. The following factors, among others, could cause actual results
    [Show full text]
  • Section B Changed Classes/Guidelines Final
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2019 Section B Changed Classes/Guidelines Final Version Date of issue: 24th December 2018 1 A3 FUNCTIONAL GASTRO-INTESTINAL DISORDER DRUGS R2003 A3A PLAIN ANTISPASMODICS AND ANTICHOLINERGICS R1993 Includes all plain synthetic and natural antispasmodics and anticholinergics. A3B Out of use; can be reused. A3C ANTISPASMODIC/ATARACTIC COMBINATIONS This group includes combinations with tranquillisers, meprobamate and/or barbiturates except when they are indicated for disorders of the autonomic nervous system and neurasthenia, in which case they are classified in N5B4. A3D ANTISPASMODIC/ANALGESIC COMBINATIONS R1997 This group includes combinations with analgesics. Products also containing either tranquillisers or barbiturates and analgesics to be also classified in this group. Antispasmodics indicated exclusively for dysmenorrhoea are classified in G2X1. A3E ANTISPASMODICS COMBINED WITH OTHER PRODUCTS r2011 Includes all other combinations not specified in A3C, A3D and A3F. Combinations of antispasmodics and antacids are classified in A2A3; antispasmodics with antiulcerants are classified in A2B9. Combinations of antispasmodics with antiflatulents are classified here. A3F GASTROPROKINETICS r2013 This group includes products used for dyspepsia and gastro-oesophageal reflux. Compounds included are: alizapride, bromopride, cisapride, clebopride, cinitapride, domperidone, levosulpiride, metoclopramide, trimebutine. Prucalopride is classified in A6A9. Combinations of gastroprokinetics with other substances
    [Show full text]